This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Leanne Larson
Senior VP, Real-World Evidence & Access at Parexel


Leanne has over twenty-five years’ experience in healthcare, featuring extensive work in pharmaceutical product development and marketing, and in healthcare technology and operational consulting. Leanne is an industry leader in developing and leading patient registries and other outcomes-research programs, and in advancing the science and application of outcomes research throughout the pharmaceutical, biotech, and medical device industries. Leanne has also worked closely with hospitals and physicians, helping them incorporate outcomes measurement within their quality and performance-improvement systems. She publishes and speaks widely on a variety of topics related to outcomes research and real-world evidence. Prior to joining PAREXEL, Leanne served as VP, Strategic Development at Quintiles/Outcome, and as VP, Cancer Intelligence with Sg2 Healthcare Intelligence, where she led their Cancer Program, tracking emerging trends and technologies impacting cancer care, and working with cancer programs across the country to optimize care delivery. Prior to Sg2, Leanne led the Registry Consulting group at ICON Lifecycle Sciences (formerly Ovation Research Group) for over 14 years, and also held positions in Ernst & Young’s Life Sciences and Pharmaceuticals consulting practice, and as a Senior Health Science Coordinator in Digestive Diseases with Merck and Co. Leanne holds a Master of Health Administration from Governors State University and a Bachelor of Science in Community Health from the University of Illinois. She is also an Instructor in Health Service Systems at the Keller Graduate School of Management, and is a Charter Member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), as well as an Invited Reviewer and Adviser for The Centers for Disease Control and Prevention (CDC).

Agenda Sessions

  • The pharma perspective: The unintended positive consequences of COVID-19


Speakers at this event